Alectinib Versus Crizotinib in Treatment-Naive ALK+ NSCLC Alectinib Versus Crizotinib in Treatment-Naive ALK+ NSCLC

Compared with crizotinib, alectinib significantly delays CNS progression in patients with advanced ALK+ NSCLC.Annals of Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news